Pacira BioSciences (PCRX) Other Operating Expenses (2010 - 2026)

Pacira BioSciences' Other Operating Expenses history runs 17 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 136.8% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $169.0 million, a 48.27% decrease from a year earlier, with the FY2025 full-year figure at $221.1 million, down 44.53% from the prior year.
• Other Operating Expenses declined to $2.3 million in Q1 2026 per PCRX's latest filing, from $55.5 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $213.5 million in Q3 2024 and bottomed at -$12.1 million in Q1 2023.
• The 5-year median for Other Operating Expenses is $55.5 million (2025), against an average of $48.6 million.
• Across the five-year window, Other Operating Expenses jumped 12468.49% in 2022 and sank 179.16% in 2023, its largest moves.
• Year by year, Other Operating Expenses stood at $100.4 million in 2022, then sank by 37.42% to $62.8 million in 2023, then fell by 6.01% to $59.0 million in 2024, then slipped by 6.04% to $55.5 million in 2025, then plunged by 95.9% to $2.3 million in 2026.
• Per Business Quant, the three latest PCRX Other Operating Expenses figures stand at $2.3 million (Q1 2026), $55.5 million (Q4 2025), and $55.4 million (Q3 2025).